Malaysia
Search
Sign In
Change Password
Points
Sign Out
Multidisciplinary
Top Medical News
In the treatment of patients with systemic lupus erythematosus (SLE), long-term use of the type I interferon inhibitor anifrolumab leads to sustained improvements in disease activity, quality of life, and serologic measures, according to the results of the open-label extension study.
The long-term risk of stroke seems to be higher in patients after transcatheter aortic valve replacement (TAVR), though some uncertainty remains whether such an effect is caused by predisposing risk factors or not, a recent study has found.
Two interleukin-6 receptor antagonists – tocilizumab and sarilumab – fared better than standard of care in improving survival and speeding up recovery in critically ill patients with COVID-19, according to findings of the REMAP-CAP* trial.
Use of antiseizure medication appears to carry an increased risk of fragility fracture in children with epilepsy, especially when treatment is initiated around the time of puberty, according to a study.
Patients with osteoarthritis (OA) can safely continue taking their nonsteroidal anti-inflammatory drugs (NSAIDs), which have been shown to have a null effect on the risk of contracting COVID-19 or all-cause mortality, as reported in a study.
Paired box gene 8 (PAX8) has been shown to be a valuable diagnostic marker in certain individuals with intraocular tumours, according to a study.
Use of allopurinol results in a 58-percent reduced risk of hepatotoxicity among thiopurine users, while myelotoxicity rates are not affected, according to a study. Moreover, thiopurine persistence is extended by 2.1 years in allopurinol users.
Special Reports
In a webinar held on 27 March 2021, paediatric
endocrinology nurses Karen Blair,
Kate Davies, and Siti Zarina Yaakop shared
insights and clinical experience based
on their frontline roles in caring for patients
with central precocious puberty (CPP)
and supporting their family members.
Intensive care unit (ICU) patients are at risk of developing serious infections with multidrug-resistant organisms (MDROs), which require appropriate and adequate antibiotic coverage. Early empirical coverage is pivotal in saving patients’ lives. At a recent webinar co-organized by the Society of Infectious Disease (Singapore) and Pfizer, renowned Professor David Paterson, Professor of Medicine and Director, The University of Queensland Centre for Clinical Research, and Consultant Infectious Diseases Physician, Royal Brisbane and Women’s Hospital, Brisbane, Australia, discussed the role of newer antimicrobial agents, including ceftazidime-avibactam (Zavicefta) in the management of MDROs in the ICU. Dr Wong Sin Yew, Infectious Disease Physician at Gleneagles Medical Centre and Mount Elizabeth Novena Specialist Centre, Singapore, chaired the event.
In Singapore, advanced breast cancer (aBC) is the leading cause of cancer death in women 30–49 years of age. For premenopausal women diagnosed with hormone receptor (HR)-positive, HER2-negative BC, cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors provide new hope. Currently, ribociclib is the only CDK4/6 inhibitor studied in the first-line setting for premenopausal women with HR+/HER2- aBC, in the phase III MONALEESA-7 trial. Two experts, Dr Wong Seng Weng, Medical Director & Consultant Medical Oncologist at The Cancer Centre, Paragon Medical & Mount Elizabeth Novena Specialist Centre, and Dr Lee Guek Eng, Senior Consultant & Specialist in Medical Oncology at Icon Cancer Centre and Program Director of the Young Women Cancer Program, weigh in with their views on managing premenopausal women with aBC.
Chronic coronary syndrome (CCS) remains a leading cause of death and disability worldwide. The dual goals of CCS management is to prevent future cardiac events, such as myocardial infarction and death, and to reduce ischaemia and relieve angina symptoms, says Prof Peter Yan, consultant cardiologist and medical director, Peter Yan Cardiology Clinic, Gleneagles Medical Centre, Singapore, during a Servier-sponsored virtual symposium.
SALOFALK – Mesalazine 1.5 g PR granules
During a recent GSK webinar, Professor Norbert Berend and Dr Gur Levy discussed the principles of asthma management and its applications, specifically addressing and challenging the use of maintenance and reliever therapy (MART). Additionally, they also highlighted recent updates on the budesonide/formoterol PRN regimen.
Primary immunodeficiency disease (PIDD) and allergies are two groups of conditions related to the immune system. However, they are uniquely different in terms of symptoms and treatment.
Conference Reports
Updated analyses of the phase III IMvigor130 trial presented at AACR 2021 revealed the overall survival (OS) benefit of atezolizumab for previously untreated locally advanced or metastatic urothelial carcinoma (mUC), be it alone or with platinum/gemcitabine chemotherapy (CT).
The novel CGRP receptor antagonist zavegepant administered intranasally effectively reduces pain and the most bothersome symptom (MBS) in patients with migraine, shows a study presented at the AAN 2021 Annual Meeting.
Having a healthy lifestyle could reduce the risk of lethal prostate cancer even in men with a high genetic risk for the disease, a recent study showed.
Hormonal therapy with a levonorgestrel-releasing intrauterine device (LNG-IUD) led to a high pathological complete response (pCR) rate in women with early-stage endometrial cancer, according to the feMMe trial presented at SGO 2021 Meeting.
Bright light therapy done at midday may be an effective and affordable adjunct to antimanic medication in patients with bipolar depression (BD), according to an expert who presented at APA 2021. This brings renewed attention to this natural, somatic treatment primarily used for seasonal depression.
The addition of the oral, small-molecule tyrosine kinase inhibitor apatinib to pegylated liposomal doxorubicin (PLD) led to a significant improvement in progression-free survival (PFS) among women with platinum-resistant or refractory recurrent ovarian cancer* compared with PLD alone, according to the results of the APPROVE trial presented at SGO 2021.
Maintenance treatment with olaparib showed progression-free survival (PFS) benefit in patients with platinum-sensitive relapsed ovarian cancer (PSR OC), particularly those with somatic BRCA mutation (BRCAm), according to results of the ORZORA* trial presented at SGO 2021.
Multimedia
